All News

acr_session2.jpeg

ACR25 Best Abstracts - Day 4

d Jack Cush, MD

Here's the last installment of our "ACR Best" abstracts as chosen by the RheumNow faculty.  Most of these were from the final, day 4, but a few were noteworthy holdovers from day 3. Enjoy!

Read Article
RheumNow Podcast square

Halloween ACR Guidance (10.31.25)

d Jack Cush, MD

Dr. Jack Cush recaps ACR2025 with suggestions on how to best learn ACR25 content from RheumNow.com and our articles, videos and podcasts.

Read Article
late breaking

Why I love the late breaking abstracts

d David Liew, FRACP

Every year I love the late breaking abstracts. It’s consistently my favourite part of the meeting program, by some distance. Here's why you should love them, too.

Read Article
question mark

Where are we at with PD-1 agonism?

d David Liew, FRACP

Promising novel mechanisms of action always create excitement, but the immune checkpoint PD-1 has cemented itself in the news far more than most. This fame is primarily from therapeutic inhibition in cancer and rheumatological inflammatory sequelae that emerge, but invoking the inverse and using PD-1 agonism to treat classical autoimmunity has subsequently been making its own mark. Given the evident plausibility, how do we feel about invoking the opposite and agonising PD-1 in classical autoimmunity?

Read Article
Catching AxSpA Early: Closing the Diagnostic Gap Dr. Akhil Sood reports on abstract 2635 and abstract 2636 presented at #ACR25. https://t.co/TmJQKQUu9E https://t.co/6dWf8DY2W3

Links:

Dr. John Cush RheumNow ( View Tweet)
RA: Inject the Steroids Dr. Richard Conway reports on abstract 1355, "Use of parenteral compared to oral glucocorticoids in early rheumatoid arthritis is superior for chance of being off steroids and escalation of therapy at 1 year," presented at the #ACR25. https://t.co/xFQMIpi75S
Dr. John Cush RheumNow ( View Tweet)
#ACR25 Best Abstracts - Day 1 The RheumNow Faculty have run through day one at ACR25 and come with a few of their favorites - some what you expect, but some of these are gems. https://t.co/tYY5xGOEGU https://t.co/wpQbvEcH1f

Links:

Dr. John Cush RheumNow ( View Tweet)
New Gout Therapies Show Promise in Phase III Trials At #ACR25, the American College of Rheumatology’s annual meeting, researchers presented pivotal Phase III studies highlighting novel therapeutic options for patients with gout, particularly those with limited treatment choices https://t.co/Ff16L2CHc0
Dr. John Cush RheumNow ( View Tweet)

#ACR25 Sheds Light on Disparities, Age-Related Trends, and Epidemiology in Autoimmune Rheumatic Diseases At #ACR25, new research explored critical disparities and epidemiologic trends shaping outcomes in autoimmune rheumatic diseases across diverse populations and age groups. https://t.co/CPob0ppjv3

Dr. John Cush RheumNow ( View Tweet)
💬 #ACR2025 Topic Panels — LIVE! Nov. 2 join RheumNow at 7 PM ET for a deep dives into the hottest topics in rheumatology: 👉 PsA Join Us Live on: X Live • Facebook Live • YouTube Live • LinkedIn Live • https://t.co/V10S4oVFsv Top experts. Real clinical insight. Don't miss https://t.co/A4pUjZG3Dr

Links:

Dr. John Cush RheumNow ( View Tweet)
Upadacitinib is a Double Edged Vascular Sword in GCA Dr. David Liew discusses abstracts O751, O738, and O734 presented at #ACR25. https://t.co/eTmVehP2Cd https://t.co/vxehwRWM2D

Links:

Dr. John Cush RheumNow ( View Tweet)
Hospitalization in Stills: Is it "Still" an infection? Dr. Janet Pope discusses abstract 0163, "Trends in hospitalization and outcomes among patients admitted with Adult-onset Still’s disease in the United States: INSIGHTS FROM THE NATIONAL INPATIENT SAMPLE (2016-2022)," https://t.co/3Z0U9XN3nx
Dr. John Cush RheumNow ( View Tweet)
Rheumatoid arthritis and the ‘big bang’ at #ACR25! Is there ‘bang for the buck’ using big data to help predict who will develop RA in at-risk populations and similarly to predict response to csDMARDs, TNFi and JAKi in RA? https://t.co/QDvdiP3q9R https://t.co/cz4j4vZkSd

Links:

Dr. John Cush RheumNow ( View Tweet)
SLE Conference Preview: progress in biologics at #ACR25 We now have four licensed targeted therapies (i.e., belimumab, voclosporin and obinutuzumab for active lupus nephritis and belimumab and anifrolumab for active non-renal SLE). What are other issues to be addressed and https://t.co/uvVICAsCzo
Dr. John Cush RheumNow ( View Tweet)
AI Scribes Found their Favorite Doctors Dr. Aurelie Najm discusses abstract 0189, "“Try it, you’ll love it”: Patterns of AI Scribes Use Among Rheumatologists", presented at #ACR25 https://t.co/QTYFvLa95Y https://t.co/ZIvMovloBL

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheum Now Rheumatology Round-Up — LIVE Join Drs. Jack Cush & Arthur Kavanaugh for this livestream with two of rheumatology’s most trusted voices: this Friday, Oct 31 at 12 PM CST for break down of the latest breakthroughs and hottest topics in rheumatology from #ACR25. 📡 Live https://t.co/ZwP4UwojuZ
Dr. John Cush RheumNow ( View Tweet)
Psoriatic Arthritis Imaging Dr. Arthur Kavanaugh talks about imaging in psoriatic arthritis at #ACR25 https://t.co/l6MKTgEJXu https://t.co/sKhoQWCPli

Links:

Dr. John Cush RheumNow ( View Tweet)
Lupus in Focus: 2025 ACR Treatment Guidelines for SLE Dr. Sheila Reyes reports on the scientific session presentation of the #ACR25 treatment guidelines for SLE https://t.co/Bh1fSFf8ju https://t.co/OH8h9GDeMf

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR25 meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is selected by RheumNow and its faculty.

Dr. John Cush RheumNow ( View Tweet)

Day 1 Recap: #ACR25 Highlights Join RheumNow Faculty Drs. Aurelie Najm, Yuz Yusof, Janet Pope, and Jack Cush for Day 1 highlights from the 2025 ACR Convergence in Chicago, focusing on abstracts/sessions: 0775, SLE guidelines, 0163, 0832, 0776, 0792, and 0164. https://t.co/ODte4XY82a
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×